Factor V Leiden Deficiency and Thrombosis Risk: Genetics, Mechanisms, and Prevention

Clarification: Factor V Leiden is a gain‑of‑function mutation (Arg506Gln) causing activated protein C resistance, not a deficiency. It increases thrombosis risk; true factor V deficiency is a rare bleeding disorder. This article addresses the common thrombophilic variant.

Pathophysiology

  • Normal factor V is inactivated by activated protein C (APC), limiting thrombin generation.
  • Factor V Leiden resists APC inactivation → prolonged procoagulant activity → hypercoagulable state.

Inheritance and Risk

  • Autosomal dominant.
  • Heterozygous (1 copy): 3–8× increased VTE risk; ~5% of Caucasians carry it.
  • Homozygous (2 copies): 50–100× risk; earlier, more severe events.

Clinical Manifestations

  • Deep vein thrombosis (DVT), pulmonary embolism (PE).
  • Pregnancy‑associated VTE, recurrent miscarriage (placental thrombosis).
  • Unusual sites: cerebral venous sinus, portal vein thrombosis.

Risk Modifiers

  • Age, obesity, smoking, estrogen (OCPs, HRT), pregnancy, surgery, immobilization, malignancy.

Prevention Strategies

  • Weight management, regular activity, avoid prolonged immobility.
  • Compression stockings for long travel or hospitalization.
  • Avoid estrogen‑containing contraceptives; consider progestin‑only or non‑hormonal options.
  • Anticoagulation prophylaxis during high‑risk situations (surgery, hospitalization).
  • Long‑term anticoagulation only after unprovoked VTE or recurrent events (individualized decision).

Testing and Counseling

Targeted testing for first‑degree relatives of known carriers. Genetic counseling helps interpret results and guide family planning.

Blood Disorders - Related Articles